<DOC>
	<DOC>NCT03073200</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.</brief_summary>
	<brief_title>Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Have a diagnosis of moderatetosevere plaquetype psoriasis for at least 6 months prior to baseline as determined by the investigator. Have PASI score ≥12 and a sPGA ≥3 and body surface area involvement ≥10% at screening and baseline. Are candidates for phototherapy or systemic treatment or considered by the investigator as not adequately controlled by topical therapies. Male subjects agree to use a reliable method of birth control during the study. Female subjects are women of childbearing potential who test negative for pregnancy and agree to use a reliable method of birth control or remain abstinent during the study and for at least 12 weeks following the last dose of investigational product, whichever is longer. Both the child or adolescent and a parent or legal guardian are able to understand and fully participate in the activities of the clinical study and sign their assent and consent, respectively. All immunizations are uptodate in agreement with current immunization guidelines, in the opinion of the investigator. Have pustular, erythrodermic, and/or guttate forms of psoriasis. Have druginduced psoriasis. Have clinical and/or laboratory evidence of untreated latent or active tuberculosis (TB). Participants with a documented history of immune deficiency syndrome. Have any other active or recent infection, including chronic or localized infections, within 4 weeks of baseline. Subjects with a known history of malignancy, lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly. Have used any therapeutic agent targeted at reducing interleukin17. Have received other therapies within the specified timeframes below: adalimumab and infliximab 60 days, abatacept 90 days, anakinra 7 days, or any other biologic diseasemodifying antirheumatic drug 5 halflives prior to baseline. systemic therapy for psoriasis and psoriatic arthritis (PsA) (other than above, eg, methotrexate, cyclosporine), phototherapy (eg, photochemotherapy [psoralen plus ultraviolet A]) in the previous 4 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>children</keyword>
	<keyword>psoriasis treatment</keyword>
	<keyword>adolescents</keyword>
</DOC>